Versant Ventures
Versant Ventures caters to the healthcare sector with early and later stage venture, private equity, and debt financing investments.
Business Model:
Revenue: $6M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Versant Ventures Information
Geographic Data
Address: One Sansome Street
City: San Francisco
State: CA
Zip: 94104
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
3,552,464Website Global Rank
3,632Website Monthly Traffic
Twitter Followers
Description
Versant Ventures is a healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in Canada, the U.S., and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.
Contact Phone:
+14158018100
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2008 | Novasys Health | Venture Round | 49.5M |
| 7/2006 | Pathwork Diagnostics | Venture Round | 11M |
| 1/2008 | Benvenue Medical | Series B | 15M |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 11/2003 | Cameron Health | Series B | 29M |
| 9/2010 | Nuvaira | Series A | 3M |
| 9/2002 | Glaukos | Series A | 10M |
| 12/2016 | BlueRock Therapeutics | Series A | 225M |
| 5/2008 | Novasys Medical, Inc. | Series D | 49.5M |
| 9/2005 | Kythera Biopharmaceuticals | Seed Round | 1M |
| 4/2008 | Anaphore | Venture Round | 8M |
| 1/2009 | Anaphore | Series A | 25M |
| 4/2005 | NovaCardia | Series A | - |
| 6/2012 | Halscion, Inc. | Debt Financing | 4.3M |
| 10/2005 | Cameron Health | Series C | 15M |
| 12/2000 | Confirma | Series B | 12M |
| 9/2006 | NovaCardia | Series B | 48M |
| 6/2004 | Aria Biosystems | Series A | 5.5M |
| 4/2014 | Nuvaira | Series D | 42M |
| 3/2008 | Ocular Therapeutix | Series B | 6M |
| 4/2009 | Ambrx | Series D | 10M |
| 12/2018 | Black Diamond Therapeutics | Series A | 20M |
| 10/2012 | Cotera | Venture Round | 5M |
| 12/2016 | Veran Medical Technologies | Venture Round | 31M |
| 1/2004 | Standard BioTools | Series D | 21M |
| 6/2009 | Anaphore | Series A | 13M |
| 9/2019 | Anokion | Series B | 40M |
| 3/2012 | OpGen | Series C | 0 |
| 8/2007 | MedManage Systems | Series E | 5M |
| 12/2011 | Groove Biopharma | Series B | 6M |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 1/2007 | Standard BioTools | Series E | 0 |
| 1/2011 | SpaceOAR | Debt Financing | 3M |
| 3/2013 | Novira Therapeutics | Series A | 0 |
| 10/2009 | Halscion, Inc. | Venture Round | 6M |
| 9/2003 | ParAllele Bioscience | Series B | 22.5M |
| 3/2007 | Amira Pharmaceuticals | Series B | 25M |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 11/2001 | Standard BioTools | Series C | 34M |
| 4/2023 | Abdera Therapeutics | Series A | - |
| 1/2023 | Belharra Therapeutics | Series A | 0 |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Cimeio Therapeutics | Series A | 0 |
| 2/2011 | Ocular Therapeutix | Series D | 14M |
| 5/2010 | Sequent Medical | Series B | 15.6M |
| 10/2020 | VectivBio | Equity | 110M |
| 12/2006 | NeoVista | Series C | 41M |
| 3/2014 | Bird Rock Bio | Series B | 0 |
| 1/2009 | Bird Rock Bio | Series A | 25M |
| 10/2007 | Vital Therapies | Series C | 28.1M |
| 4/2004 | MedManage Systems | Series C | 6M |
| 4/2014 | CRISPR Therapeutics | Series A | 25M |
| 7/2006 | Cameron Health | Series D | 31M |
| 10/2012 | Cerephex | Series A | 5.9M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 7/2008 | OraMetrix | Series C | 0 |
| 3/2012 | GluMetrics | Venture Round | 13.3M |
| 11/2011 | Hicuity Health | Series D | 0 |
| 6/2002 | Intuity Medical | Series A | 3M |
| 8/2012 | Intuity Medical | Venture Round | 12M |
| 11/2008 | CodeRyte | Series D | 0 |
| 6/2007 | CELLutions Biosystems | Series B | 7M |
| 1/2017 | Jecure Therapeutics | Series A | 20M |
| 8/2006 | Intuity Medical | Series C | 20M |
| 4/2004 | ROX Medical | Series A | 3.6M |
| 6/2015 | Inari Medical | Series B | 12.4M |
| 9/2016 | Rox Medical | Series E | 40M |
| 3/2009 | Rennovia | Series A | 16.3M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 6/2012 | Benvenue Medical | Series D | 25M |
| 1/2019 | Halio | Series D | 100M |
| 6/2014 | Benvenue Medical | Series E | 40M |
| 6/2002 | Salmedix | Series B | 27.5M |
| 2/2005 | Five Prime Therapeutics | Series C | 45M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 5/2020 | Ventus Therapeutics | Series A | 60M |
| 8/2019 | Chinook Therapeutics | Series A | 65M |
| 12/2003 | Confirma | Venture Round | 3M |
| 9/2010 | OpGen | Series B | 0 |
| 1/2008 | Nexis Vision | Series A | 6M |
| 6/2012 | Twelve | Series B | 15M |
| 1/2006 | ForSight Labs | Venture Round | 2.4M |
| 3/2006 | Helicos BioSciences | Series B | 40M |
| 9/2005 | Standard BioTools | Series D | 0 |
| 9/2012 | Nuvaira | Series B | 10.6M |
| 4/2007 | ForSight Labs | Series A | 5M |
| 4/2008 | SpaceOAR | Series A | 0 |
| 3/2004 | Jazz Pharmaceuticals | Series B | 0 |
| 1/2004 | Amphora Discovery | Series B | 12.9M |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 1/2018 | Metavention | Series C | 0 |
| 12/2012 | Minerva Surgical | Venture Round | 20M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 8/2002 | Concuity | Series C | 16.3M |
| 8/2010 | Respicardia | Series C | 0 |
| 5/2015 | NeuWave Medical | Series C | 25.3M |
| 11/2006 | Amira Pharmaceuticals | Series A | 4M |
| 10/2015 | Audentes Therapeutics | Series C | 65M |
| 3/2009 | Inogen | Series E | 3M |
| 2/2006 | Ablation Frontiers | Series B | 15.1M |
| 6/2004 | Ablation Frontiers | Series A | 3.6M |
| 10/2018 | Gotham Therapeutics | Series A | 54M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 1/2022 | Nested Therapeutics | Seed Round | 35M |
| 5/2016 | Nouscom | Series A | 13.6M |
| 6/2013 | ForSight Labs | Series B | 9.3M |
| 4/2005 | ParAllele Bioscience | Convertible Note | 6M |
| 7/2008 | Hicuity Health | Series B | 5M |
| 5/2012 | NeoVista | Venture Round | 6M |
| 1/2001 | Cameron Health | Series A | - |
| 3/2009 | NovaLign Orthopaedics | Series B | 10M |
| 5/2014 | Ceterix Orthopaedics | Series B | 18M |
| 1/2006 | Ambrx | Series B | 5M |
| 7/2006 | GluMetrics | Series B | 9M |
| 11/2017 | Nouscom | Series B | 48.8M |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 8/2022 | Vector BioPharma | Series A | 0 |
| 7/2019 | Century Therapeutics | Series A | 250M |
| 9/2003 | NovaCardia | Venture Round | 22M |
| 1/2014 | Intuity Medical | Venture Round | 5.5M |
| 10/2008 | Lutonix | Series B | 20M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 3/2012 | Sequent Medical | Series C | 26M |
| 10/2013 | Inceptus | Series A | 4.7M |
| 7/2005 | Nanoplex Technologies | Series B | 2.5M |
| 12/2005 | Acclarent | Series B | 25M |
| 5/2004 | NeoVista | Series A | 2M |
| 7/2006 | ROX Medical | Series B | 10.1M |
| 2/2013 | Nuvaira | Series C | 10M |
| 11/2012 | CardiAQ Valve Technologies | Series B | 37.3M |
| 1/2018 | Intuity Medical | Venture Round | 0 |
| 11/2016 | Intuity Medical | Venture Round | 0 |
| 6/2008 | ROX Medical | Series C | 33M |
| 10/2013 | Inari Medical | Series A | 4.7M |
| 9/2021 | 858 Therapeutics | Series A | 0 |
| 12/2008 | Hotspur Technologies | Series A | 1.3M |
| 1/2001 | Salmedix | Series A | - |
| 7/2005 | Integrated Diagnostics | Series A | - |
| 3/2005 | Ambrx | Series A | 23.4M |
| 3/2014 | PIQUR Therapeutics | Series A | 32M |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 6/2018 | Akero Therapeutics | Series A | 65M |
| 9/2014 | Ivantis | Series B | 25M |
| 11/2006 | Intersection Medical Inc | Series B | 5M |
| 8/2011 | Intuity Medical | Series D | 12M |
| 9/2015 | Veran Medical Technologies | Venture Round | 0 |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 11/2004 | Accelerator Corp. | Venture Round | 0 |
| 1/2009 | Synosia Therapeutics | Series B | 0 |
| 1/2009 | AlterG | Series B | 8M |
| 4/2012 | Five Prime Therapeutics | Private Equity Round | 10M |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 1/2010 | The Foundry | Series A | 3M |
| 1/2016 | Benvenue Medical | Equity | 23M |
| 6/2013 | Veracyte | Series C | 28M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 8/2001 | Insulet | Series B | 11M |
| 10/2011 | Realeve | Series C | 32M |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 2/2019 | Nuvaira | Equity | 79M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 11/2002 | Skylight Healthcare Systems | Series B | 7.8M |
| 1/2018 | Pandion Therapeutics | Series A | 58M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 11/2003 | NeoGuide Systems | Series B | 0 |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 1/2017 | Halio | Series C | 65M |
| 8/2020 | T-knife | Series A | 78.4M |
| 12/2017 | Respicardia | Venture Round | 0 |
| 7/2013 | Audentes Therapeutics | Series A | 30M |
| 1/2017 | Therachon | Series A | 5M |
| 4/2014 | AAVLife | Series A | 12M |
| 9/2021 | iECURE | Series A | 50M |
| 9/2019 | Repare Therapeutics | Series B | 82.5M |
| 8/2018 | Therachon | Series B | 60M |
| 6/2015 | Sebacia | Series C | 12M |
| 4/2014 | Sequent Medical | Series D | 20M |
| 8/2006 | ImpediMed | Venture Round | 3.4M |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 10/2013 | Immune Design | Series C | 49M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 7/2004 | LipoSonix | Series C | 27M |
| 4/2011 | Halscion, Inc. | Venture Round | 3.5M |
| 4/2007 | NovaCardia | Series B | 18M |
| 7/2006 | Ambrx | Series C | 52M |
| 8/2008 | Glaukos | Series D | 35M |
| 6/2009 | Nexis Vision | Series B | 12M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 9/2019 | Passage Bio | Series B | 110M |
| 8/2021 | Jnana Therapeutics | Series B | 50M |
| 10/2004 | Concuity | Venture Round | 8.3M |
| 11/2017 | Oyster Point Pharmaceuticals | Series A | 22M |
| 12/2000 | Skylight Healthcare Systems | Series A | - |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 6/2002 | Spiration | Series D | 22M |
| 9/2015 | Therachon | Series A | 35M |
| 11/2006 | Neurotech | Series B | 0 |
| 1/2020 | VectivBio | Series A | 35M |
| 12/2022 | Launchpad Therapeutics | Series A | 0 |
| 7/2020 | Bright Peak Therapeutics | Series A | 35M |
| 10/2015 | Turnstone Biologics | Series A | 11.3M |
| 10/2020 | RayzeBio | Series A | 45M |
| 9/2012 | Rox Medical | Series D | 6M |
| 7/2015 | PIQUR Therapeutics | Series A | 19M |
| 1/2008 | Inogen | Series E | 12.7M |
| 9/2009 | Helicos BioSciences | Post-IPO Equity | 10M |
| 8/2012 | AlterG | Series C | 10M |
| 10/2010 | Synosia Therapeutics | Series C | 0 |
| 10/2009 | SpaceOAR | Series B | 6.1M |
| 11/2006 | Impedance Cardiology Systems | Series B | 5M |
| 12/2021 | CODA Biotherapeutics | Venture Round | 0 |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 1/2007 | Synosia Therapeutics | Venture Round | 32.5M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 2/2007 | Trius Therapeutics | Series A | 20M |
| 12/2014 | Audentes Therapeutics | Series B | 42.5M |
| 4/2014 | RedBrick Health | Venture Round | 7.5M |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 3/2021 | Century Therapeutics | Series C | 0 |
| 4/2020 | Pandion Therapeutics | Series B | 80M |
| 2/2007 | Inogen | Series D | 22M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 11/2021 | ViaLase | Series A | 27.3M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 2/2017 | Vividion Therapeutics | Series A | 50M |
| 2/2008 | PhaseRx | Series A | 20.2M |
| 1/2017 | Ebb Therapeutics | Series B | 0 |
| 6/2017 | Repare Therapeutics | Series A | 68M |
| 2/2006 | Amphora Discovery | Series E | 4.4M |
| 12/2001 | Pharmion | Venture Round | 65M |
| 3/2018 | Inari Medical | Series C | 20.9M |
| 3/2008 | Spiration | Series G | 18.5M |
| 2/2007 | Vantage Oncology | Series D | 0 |
| 2/2019 | Oyster Point Pharmaceuticals | Series B | 0 |
| 5/2014 | Anokion | Series A | 37.5M |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 11/2022 | iECURE | Series A | 0 |
| 2/2012 | Helicos BioSciences | Series A | 27M |
| 9/2010 | Okairos | Series B | 20.5M |
| 12/2017 | Jnana Therapeutics | Series A | 50M |
| 5/2003 | Accelerator Corp. | Venture Round | 0 |
| 3/2009 | NeoVista | Series D | 18M |
| 8/2021 | T-knife | Series B | 110M |
| 3/2013 | Theraclone Sciences | Series B | 0 |
| 9/2008 | ForteBio | Series C | 25M |
| 7/2008 | Immune Design | Series A | 18M |
| 10/2002 | Insulet | Series C | 22M |
| 6/2009 | Ocular Therapeutix | Series C | 15M |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 8/2005 | Amira Pharmaceuticals | Series A | 3M |
| 10/2002 | Pharmion | Venture Round | 40M |
| 2/2018 | Quentis | Series A | 48M |
| 12/2019 | Pipeline Therapeutics | Series B | 0 |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 11/2006 | NewHope Bariatrics | Private Equity Round | 18.5M |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 1/2004 | Spiration | Series E | 0 |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 8/2006 | Vantage Oncology | Series C | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 5/2005 | Vantage Oncology | Series C | 0 |
| 5/2020 | Monte Rosa Therapeutics | Series A | 32.5M |
| 4/2007 | Acclarent | Series C | 35M |
| 6/2021 | Stablix | Series A | 63M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 6/2004 | Vantage Oncology | Series B | 0 |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 4/2006 | MedManage Systems | Series D | 10.8M |
| 4/2021 | Capsida | Series A | 50M |
| 9/2014 | Zyga Technology | Series D | 2M |
| 3/2002 | Phenomix | Series A | 12M |
| 3/2004 | Insulet | Series D | 35.5M |
| 9/2014 | AcuFocus | Venture Round | 0 |
| 11/2018 | Aprea | Series C | 0 |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 10/2003 | Biospect | Series B | 27M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 6/2004 | Inogen | Series B | 6M |
| 2/2009 | WaveTec Vision | Series C | 20.1M |
| 5/2012 | Zyga Technology | Series C | 25M |
| 5/2011 | WaveTec Vision | Series D | 15.9M |
| 9/2007 | OpGen | Venture Round | 0 |
| 7/2017 | Sebacia | Series D | 0 |
| 10/2006 | Achaogen | Series B | 26M |
| 4/2010 | Groove Biopharma | Series A | 3.9M |
| 7/2010 | Immune Design | Series B | 32M |
| 1/2008 | Confirma | Series C | 0 |
| 10/2005 | ForteBio | Series B | 17.3M |
| 7/2017 | Venatorx Pharmaceuticals | Series B | 42M |
| 9/2001 | Amphora Discovery | Series A | 35M |
| 2/2006 | Insulet Corporation | Series E | 0 |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 1/2010 | Intuity Medical | Series D | 64M |
| 5/2007 | WaveTec Vision | Series B | 13M |
| 1/2004 | Intuity Medical | Series B | 0 |
| 6/2021 | LENZ Therapeutics | Series A | 47M |
| 6/2020 | Lycia Therapeutics | Series A | 50M |
| 12/2020 | Gritstone Bio | Post-IPO Equity | 125M |
| 4/2006 | Spiration | Series F | 13.4M |
| 1/2004 | Novacea | Series C | 35M |
| 9/2020 | Graphite Bio | Series A | 45M |
| 11/2002 | Novacea | Series B | 36M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2004 | Amphora Discovery | Series C | 20M |
| 10/2008 | Respicardia | Series B | 0 |
| 1/2011 | Ocular Therapeutix | Series C | 6M |
| 8/2008 | GluMetrics | Series C | 20.1M |
| 11/2011 | AcuFocus | Private Equity Round | 0 |
| 6/2008 | Cameron Health | Series E | 0 |
| 4/2015 | Twelve | Series C | 35M |
| 4/2008 | Bird Rock Bio | Series A | 8M |
| 4/2013 | RedBrick Health | Private Equity Round | 14M |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 6/2013 | Ocular Therapeutix | Series D | 23.8M |
| 12/2015 | Kyras Therapeutics | Series A | - |
| 2/2011 | Glaukos | Series E | 0 |
| 9/2006 | NeoVista | Series B | 26M |
| 10/2021 | Tentarix Biotherapeutics | Series A | 50M |
| 8/2012 | ForSight VISION5 | Venture Round | 8M |
| 4/2011 | Benvenue Medical | Series C | 35.5M |
| 3/2009 | LensX Lasers | Series B | 22.4M |
| 4/2014 | ForSight VISION5 | Equity | 15M |
| 4/2014 | ForSight Labs | Series C | 15M |
| 4/2015 | CRISPR Therapeutics | Series A | 35M |
| 2/2017 | Tarveda Therapeutics | Series D | 30M |
| 4/2015 | CRISPR Therapeutics | Series B | 29M |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 9/2008 | Microfabrica | Series B | 22.5M |
| 5/2018 | Lava Therapeutics | Series A | 18.7M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 11/2001 | ParAllele Bioscience | Series A | - |
| 3/2018 | Tempest Therapeutics | Series B | 70M |
| 11/2016 | Turnstone Biologics | Series B | 0 |
| 7/2021 | Turnstone Biologics | Series D | 0 |
| 4/2009 | RedBrick Health | Series C | 15M |
| 5/2009 | Realeve | Series B | 20M |
| 9/2020 | Lava Therapeutics | Series C | 83M |
| 8/2011 | RedBrick Health | Series D | 5M |
| 6/2010 | Veracyte | Series B | 28M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 1/2007 | AcuFocus | Series D | 0 |
| 1/2013 | GluMetrics | Debt Financing | 5.6M |
| 12/2008 | CELLutions Biosystems | Series B | 8.8M |
| 6/2017 | Monteris Medical | Series C | 26.6M |
| 12/2007 | RedBrick Health | Series B | 15M |
| 12/2015 | Inception IBD | Series A | 14.1M |
| 12/2013 | Inception Sciences | Series A | 10M |
| 3/2016 | Aprea | Series B | 50.6M |
| 11/2002 | Vantage Oncology | Series A | 9M |
| 5/2001 | CardioNow | Series C | 6M |
| 8/2020 | Matterhorn Biosciences | Venture Round | 30M |
| 11/2009 | Standard BioTools | Venture Round | 0 |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 4/2023 | Abdera Therapeutics | Series A | - |
| 1/2023 | Belharra Therapeutics | Series A | 0 |
| 12/2022 | Launchpad Therapeutics | Series A | 0 |
| 11/2022 | iECURE | Series A | 0 |
| 11/2022 | Jnana Therapeutics | Series C | 0 |
| 8/2022 | Vector BioPharma | Series A | 0 |
| 4/2022 | Tempest Therapeutics | Post-IPO Equity | 0 |
| 4/2022 | Cimeio Therapeutics | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
